Baseline characteristics and objective response.
| Discovery cohort | Validation cohort | |
|---|---|---|
| Patient characteristics | n = 40 | n = 86 |
| Age, years | ||
| Median | 67 | 69 |
| Range | 51–84 | 31–85 |
| Sex, n (%) | ||
| Male | 26 (65.0) | 67 (77.9) |
| Female | 14 (35.0) | 19 (22.1) |
| Histology, n (%) | ||
| Squamous | 10 (25.0) | 24 (27.9) |
| Nonsquamous | 30 (75.0) | 62 (72.1) |
| Smoking history, n (%) | ||
| Current or former smoker | 29 (72.5) | 68 (79.1) |
| Never smoked | 11 (27.5) | 18 (20.9) |
| Disease stage, n (%) | ||
| c-stage III | 9 (22.5) | 18 (20.9) |
| c-stage IV | 22 (55.0) | 55 (64.0) |
| Postoperative recurrence | 9 (22.5) | 13 (15.1) |
| Driver mutation status, n (%) | ||
| Wild type | 33 (82.5) | 73 (84.9) |
| EGFR (19 del or L858R) | 7 (17.5) | 12 (14.0) |
| ALK | 0 (0) | 1 (1.1) |
| Objective response at 9 weeks, n (%) | ||
| CR or PR | 11 (27.5) | 12 (14.0) |
| SD | 15 (37.5) | 31 (36.0) |
| PD | 14 (35.0) | 43 (50.0) |
Abbreviations: ALK, anaplastic lymphoma kinase; CR, complete response; c-stage, clinical stage; del, deletion.